S. Staszewski

Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy

H. Brodt, B. Kamps, P. Gute, 1997, AIDS.

Preferential Amplification of CD8 Effector-T Cells after Transcutaneous Application of an Inactivated Influenza Vaccine: A Randomized Phase I Trial

C. Katlama, B. Autran, S. Staszewski, 2010, PloS one.

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

M. Moroni, F. Antunes, J. Montaner, 2003, AIDS.

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

J. Sterne, A. d’Arminio Monforte, M. Egger, 2003, The Lancet.

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies

J. Sterne, A. d’Arminio Monforte, M. Egger, 2007, AIDS.

Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.

R. Hogg, A. Phillips, B. Ledergerber, 2004, The Journal of infectious diseases.

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

B. Gazzard, J. Montaner, R. Weber, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

[Intestinal permeability in patients with acquired immunodeficiency syndrome (AIDS)].

S. Staszewski, W. Caspary, M. Ott, 1991, Klinische Wochenschrift.